NCT00849875View on ClinicalTrials.gov

A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 26, 2009

Primary Completion Date

November 17, 2014

Study Completion Date

November 17, 2014

Conditions
Melanoma
Interventions
BIOLOGICAL

Immunotherapeutic GSK2132231A

Intramuscular administration

DRUG

Dacarbazine

Intravenous administration Chemotherapy

Trial Locations (14)

1090

GSK Investigational Site, Brussels

1180

GSK Investigational Site, Brussels

1200

GSK Investigational Site, Brussels

4000

GSK Investigational Site, Liège

5530

GSK Investigational Site, Yvoir

8800

GSK Investigational Site, Roeselare

13385

GSK Investigational Site, Marseille

14033

GSK Investigational Site, Caen

44093

GSK Investigational Site, Nantes

51092

GSK Investigational Site, Reims

59037

GSK Investigational Site, Lille

75018

GSK Investigational Site, Paris

75475

GSK Investigational Site, Paris

94805

GSK Investigational Site, Villejuif

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY